Company intelligence / Profile preview

Mitral Technologies

Liège, Wallonia, Belgiumpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Mitral Technologies has developed a non-invasive medical device to treat patients with mitral regurgitation using the natural vascular tract. The company relocated from the United States to Liège, Belgium in 2019 and has raised over €3.2 million to continue its R&D efforts. No published clinical trial results or regulatory approvals are available as of June 2025.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Mitral Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitral Technologies.

Explore the full profile